AFP and neoplasm: With the characterization of more biomarkers and the improvement of various detection levels, a growing number of markers such as tumor markers (for example, CEA, CA19-9, CA153, CA72-4, AFP) (74), circulating free DNA (cfDNA) (75), and circulating tumor cells (CTC) (76), were used to predict the sensitivity of NACT for GC to provide clinical evidence of individualized diagnoses and treatment plans.